An NCI-designated Comprehensive Cancer Center

Steven T. Rosen, M.D.

Hematologist - Oncologist; Irell & Manella Cancer Center Director's Distinguished Chair; Morgan & Helen Chu Director's Chair of the Beckman Research Institute
Research Focus
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
Provost and Chief Scientific Officer; Director, Comprehensive Cancer Center; Director, Beckman Research Institute; Director, Irell & Manella Graduate School of Biological Sciences; Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

  • Cutaneous Lymphoma Program
  • Hematologic Cancers
  • Hematology & Hematopoietic Cell Transplantation
  • Lymphoma

Steven T. Rosen, M.D., is provost and chief scientific officer for City of Hope and a member of City of Hope's Executive Team. He also is director of the comprehensive cancer center, Beckman Research Institute of City of Hope and the Irell & Manella Graduate School of Biological Sciences, holds the Irell & Manella Cancer Center Director's Distinguished Chair and the Morgan & Helen Chu Director’s Chair of the Beckman Research Institute.

Dr. Rosen sets the scientific direction of City of Hope, shaping the research and educational vision for the biomedical research, treatment and education institution. Working closely and collaboratively with City of Hope's scientists, clinicians and administrative leaders, he develops strategies that contribute to the organization's mission.

As director of Beckman Research Institute, he works with faculty across the institution to help shape and direct the scientific vision for the institute while leading the vital basic and translational research that is fundamental to our strategic plan and mission. He focuses on opportunities for expanding and integrating our research initiatives; recruiting and leading talented scientists, helping our talented researchers achieve national and international recognition, and promoting our national standing as a premier scientific organization.

Prior to joining City of Hope, Dr. Rosen was the Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine at Northwestern University in Chicago. He served for 24 years as director of Northwestern's Robert H. Lurie Comprehensive Cancer Center. Under his leadership, the center received continuous National Cancer Institute (NCI) funding beginning in 1993 and built nationally recognized programs in laboratory sciences, clinical investigations, translational research and cancer prevention and control. The center attained comprehensive status in 1997.

Dr. Rosen has published more than 400 original reports, editorials, books and book chapters. His research has been funded by the NCI, American Cancer Society, The Leukemia & Lymphoma Society and Multiple Myeloma Research Foundation. Dr. Rosen also has served as an adviser for several of these organizations and on the external advisory boards of more than a dozen NCI-designated comprehensive cancer centers. He is the current editor-in-chief of the textbook series "Cancer Treatment & Research."

Recognized as one of the "Best Doctors in America," Dr. Rosen is a recipient of the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital and the Man of Distinction Award from the Israel Cancer Research Fund. He is also a member of the American Institute for Medical and Biological Engineering’s College of Fellows. Dr. Rosen earned his bachelor's degree and medical degree with distinction from Northwestern University, and is a member of the Alpha Omega Alpha Honor Society.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Zhang XH, Nam S, Wu J, Liu X, Li H, Mckeithan T, Gong Q, Chan W, Yin H, Yuan Y-C, Pillai R, Horne D, Chen Y, Rosen ST. Multi-kinase Inhibitor with Anti-p38y Activity in Cutaneous T cell Lymphoma. Journal of Investigative Dermatology. 2018  (In Press)
  • Seymour JF, Ma S, Brander D, Choi M, Barrientos J, Davids MS, Anderson MA, Beaven A,  Rosen ST, Tam C,  Prine B, Agarwal S,  Munasinghe W,  Zhu M, Cerri E, Verdugo M,  Kim SY, Humerickhouse R, Gordon G, Kipps T,  Roberts AW. Venetoclax plus rituximab in relapsed or refractory chronic leukaemia: a phase 1b study. Lancet Oncology. 2017 Feb;18(2):230-240. DOI: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
  • Rubio-Gonzalez B, Zain J, Garcia L, Rosen ST, Querfeld C. Cutaneous gamma-delta T-cell lymphoma – successfully treated with brentuximab vedotin. JAMA Dermatol (online Sept 21, 2016) 152:12, 2016.
  • Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas; current status and future directions, British Journal of Haematology, Volume 176, Issue 1, 26 October 2016.
  • Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam. Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved ritonavir and Metformin. Clin Cancer Res; 21(5) March 1, 2015.
  • Frankfurt O, Ma S, Goolsby C, Gordon L, Winter JN, Horowitz J, Rademaker A, Weitner BB, Petrson LC, Altman JK, Tallman MS, Petrich A, Rosen ST. Phase II Study of Alemtuzumab-Rituximab Therapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Short and Long-term Outcomes. Leukemia & Lymphoma 2015 February;56(2):315-23.
  • Bliss-Moreau M, Coarfa C, Gunaratne P, Guitart, J, Krett N, Rosen ST. Identification of p38 as a therapeutic target for treatment of  Sézary Syndrome. Journal of Investigative Dermatology 2015 February;135(2):599-608.
  • Thomas A., Coarfa C, Qian J, Wilkerson J, Rajapakshe K, Krett N, Gunaratne P, Rosen ST.  Identification of Potential Glucocorticoid Receptor Targets in Multiple Myeloma. Nuclear Receptor Signaling 2015 Vol 13. DOI: 10.1621/nrs.13006.
  • Dalva-Aydemir S, Bajpai R, Martinez M, Adekola K, Kandela I, Wei C, Singhal S, Koblinski J, Raje N, Rosen ST, Shanmugam M. Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin. Clin Cancer Res. March 1, 2015 (21) (5) 1161-1171; DOI: 10.1158/1078-0432. CCR-14-1088.
  • McBrayer S, Cheng J, Singhal S, Krett NL, Rosen ST, Shanmugam M. Multiple Myeloma exhibits Novel Dependence on GLUT4, GLUT8, and GLUT11: Implications for Glucose Transporter-Directed Therapy. Blood First Edition Paper, 3/27/2012:DOI 10.1182/Blood-2011-09-3377846.
  • Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J,Yarosh DB, Foss FM, Kuzel TM. Multicenter phase II trial of temozolomide in mycosis fungoides/Sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res 17(17); 5748-54. 2011 Jul 11.
  • Rovedo M, Krett N, Rosen ST. Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of Enzastaurin. Journal of Investigative Dermatology 2011 Jul;131(7):1442-9. DOI:10.1038/jid.2011.70.
  • Tessel MA, Benham AL, Krett NL, Rosen ST, Gunaratne PH. Role for MicroRNAs in Regulating Glucocorticoid Response and Resistance in Multiple Myeloma. Horm Cancer 2011 Jun;2(3):182-9.
  • Dennison J, Shanmugam M, Krett N, Medeiros J, Neelapu S, Rosen, ST, Gandi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood 116:5622-5630, 2010 Dec 16.
  • Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Amino-Adenosine. J. Biol. Chem 284(39):26816-30, 2009 Sep.
  • Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST. Dual Regulation of Glucocorticoid-Induced Leucine Zipper (GILZ) by the Glucocorticoid Receptor and the PI3-kinase/AKT Pathways in Multiple Myeloma. J Steroid Biochem & Molecular Biol 110:244-254, 2008 Apr 20.
  • Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore P, Chang Y. T-Antigen Mutations are a Tumor-Specific Signature for Merkel Cell Polyomavirus. PNAS USA 105(42):16272-7, 2008 Oct 21.
  • Adekola K U.A., Aydemir SD, Ma S, Zhou Z, Rosen ST, Shanmugam M. Investigating and Targeting Chronic Lymphocytic Metabolism with the HIV Protease Inhibitor Ritonavir and Metformin. Leukemia & Lymphoma 2015 February;56(2):450-9.
  • Mishra RK, Wei C, Hresko RC, Baipai R, Heitmeier M, Matulis SM, Nooka AK, Rosen, ST, Hruz PW, Schiltz GE, Shanmugan, M. In Silico Modeling-based Identification of GLUT4-selective Inhibitors for Cancer Therapy. J Biol Chem 2015 Jun 6;290(23):14441-53. DOI: 10.1074/jbc.M114.628826. Epub 2015 Apr 6.
  • Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin H, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016 Nov 8;7(45):73558-73572. DOI: 10.18632/oncotarget.12434.
In The News
An Expert's Voice
test tubes

Bold steps toward a cure: Clinical trials at City of Hope

Steven Rosen

Steven Rosen, M.D., inducted into the Association of American Physicians

City of Hope News

City of Hope awarded $7.5 million to develop better treatment for a rare, incurable cancer